FDA clears clinical trial using CAR T-Cells to fight colorectal cancer

The FDA has cleared a CU Anschutz clinical trial of an experimental CAR T-cell therapy for advanced colorectal cancer and pediatric solid tumors. Developed at CU Anschutz, the therapy targets two pathways that help tumors grow and evade the immune system. The trial will assess the therapy’s safety and ability to attack cancer in patients.